TY - JOUR
T1 - Controlled‐release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification
T2 - Release rate modulation with silicone matrices via drug solubility and membrane coating
AU - Golomb, Gershon
AU - Dixon, Mark
AU - Smith, Mary Sue
AU - Schoen, Frederick J.
AU - Levy, Robert J.
PY - 1987/4
Y1 - 1987/4
N2 - Calcification (CALC) is the most frequent cause of the clinical failure of bioprosthetic heart valves (BHV) fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. The present investigation describes the formulation, characterization, and the in vivo efficacy of prolonged controlled‐release silicone matrices containing the anticalcification agent disodium 1,1‐hydroxyethylidene diphosphonate (Na2EHDP). Controlled release of EHDP was regulated by codispersions of Na2EHDP and the less soluble salt Ca2EHDP. Prolonged and constant release rates (zero‐order) were obtained by coating silicone matrices with permeable silicone membranes, which were prepared by leaching with acetone pre‐embedded polyethyleneglycol. All EHDP‐containing matrices (co‐implanted subdermally with BHV cusps in rats) significantly inhibited BHV CALC without detectable adverse effects on bone mineral and calcium metabolism. Matrices containing Na2EHDP:Ca2EHDP ratios of 10:90 or greater with respect to Na2EHDP completely inhibited CALC. Significant inhibition of BHV CALC was also observed with prereleased matrices (5 months in vitro), thus demonstrating prolonged efficacy. It is concluded that sustained release of effective anticalcification therapy without side effects was achieved by using codispersions of calcium and sodium EHDP salts, and that a delayed and/or constant release rate of EHDP was obtained by coating reservoir‐type matrices with silicone membranes that were pre‐embedded with polyethyleneglycol.
AB - Calcification (CALC) is the most frequent cause of the clinical failure of bioprosthetic heart valves (BHV) fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. The present investigation describes the formulation, characterization, and the in vivo efficacy of prolonged controlled‐release silicone matrices containing the anticalcification agent disodium 1,1‐hydroxyethylidene diphosphonate (Na2EHDP). Controlled release of EHDP was regulated by codispersions of Na2EHDP and the less soluble salt Ca2EHDP. Prolonged and constant release rates (zero‐order) were obtained by coating silicone matrices with permeable silicone membranes, which were prepared by leaching with acetone pre‐embedded polyethyleneglycol. All EHDP‐containing matrices (co‐implanted subdermally with BHV cusps in rats) significantly inhibited BHV CALC without detectable adverse effects on bone mineral and calcium metabolism. Matrices containing Na2EHDP:Ca2EHDP ratios of 10:90 or greater with respect to Na2EHDP completely inhibited CALC. Significant inhibition of BHV CALC was also observed with prereleased matrices (5 months in vitro), thus demonstrating prolonged efficacy. It is concluded that sustained release of effective anticalcification therapy without side effects was achieved by using codispersions of calcium and sodium EHDP salts, and that a delayed and/or constant release rate of EHDP was obtained by coating reservoir‐type matrices with silicone membranes that were pre‐embedded with polyethyleneglycol.
UR - http://www.scopus.com/inward/record.url?scp=0023227630&partnerID=8YFLogxK
U2 - 10.1002/jps.2600760402
DO - 10.1002/jps.2600760402
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 3110404
AN - SCOPUS:0023227630
SN - 0022-3549
VL - 76
SP - 271
EP - 276
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 4
ER -
